The aim of this study is to analyze the association between lncRNA HOXA-AS2 in circulating tumor cells (CTC) and the radiotherapy sensitivity of colon cancer. The researchers detected the expression of HOXA-AS2 in cancer tissues and peripheral blood CTC of colon cancer patients with radiotherapy sensitivity and radiotherapy tolerance by RT-PCR method. Subsequently, radiotherapy-tolerant colon cancer cells were cultured in vitro, and HOXA-AS2 was silenced by cell transfection, followed by radiation therapy. The apoptosis of cells after radiotherapy was observed by MTT assay. The results showed that compared with radiotherapy-tolerant patients, HOXA-AS2 was significantly down-expressed in cancer tissues and CTC of radiotherapy-sensitive patients, and the difference was statistically significant (P<0.05). The radiotherapy sensitivity of colon cancer cells with silenced HOXA-AS2 was significantly improved, and the difference was also statistically significant (P<0.05). This indicates that the high expression of HOXA-AS2 in CTC is negatively associated with the radiotherapy sensitivity of colon cancer cells.

Cheng Duanhui, Huang Weizheng, Lai Yingsen, Lei Guojian. Correlation Analysis between lncRNA HOXA-AS2 of Circulating Tumor Cells and Radiotherapy Sensitivity in Colon Cancer. Frontiers in Medical Science Research (2024), Vol. 6, Issue 2: 28-31. https://doi.org/10.25236/FMSR.2024.060205.

[1] Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics [J]. Trends Pharmacol Sci. 2023;44(4):222-236.

[2] Wang H, Li X, Peng R, Wang Y, Wang J. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. Semin Cancer Biol. 2021;71:21-32.

[3] Chan HT, Nagayama S, Otaki M, et al. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients[J]. Front Oncol. 2023; 12: 1055968.

[4] Cortés-Hernández LE, Eslami-S Z, Pantel K, Alix-Panabières C. Circulating Tumor Cells: From Basic to Translational Research[J]. Clin Chem. 2024;70(1):81-89.

[5] Witz A, Dardare J, Betz M, Gilson P, Merlin JL, Harlé A. Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?[J]. Clin Exp Med. 2024;24(1):2. 

[6] Chen R, Wang X, Zhou S, Zeng Z. LncRNA HOXA-AS2 Promotes Tumor Progression by Suppressing miR-567 Expression in Oral Squamous Cell Carcinoma[J]. Cancer Manag Res. 2021;13:5443-5455.

[7] Wang J, Su Z, Lu S, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer[J]. Clin Chim Acta. 2018;485:229-233.

[8] Sun J, Wang L. HOXA-AS2 enhances GBM cell malignancy by suppressing miR-2116-3p thereby upregulating SERPINA3[J]. BMC Cancer. 2022;22(1):366.

[9] Zhang F, Zhang G, Zhang H, et al. HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis[J]. Front Genet. 2022;13:944278.

[10] Wang Q, Zhang W, Deng C, Lin S, Zhou Y. HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis[J]. Front Oncol. 2022;12:1030825.

[11] Soghala S, Harsiny K, Momeni P, et al. Down-regulation of LINC-ROR, HOXA-AS2 and MEG3 in gastric cancer[J]. Heliyon. 2022;8(10):e11155.

[12] Rajabi A, Riahi A, Shirabadi-Arani H, Moaddab Y, Haghi M, Safaralizadeh R. Overexpression of HOXA-AS2 LncRNA in Patients with Gastric Cancer and Its Association with Helicobacter pylori Infection[J]. J Gastrointest Cancer. 2022;53(1):72-77.

[13] Gao K, Lv A, Zhang Q, Li Y, Yue Z, Xu S. Long noncoding RNA HOXA-AS2 ameliorates chronic intermittent hypoxia-induced lung inflammation by regulating miR-17-5p/tipe2 axis[J]. Allergol Immunopathol (Madr). 2023;51(2):36-44.

[14] Wu Q, Lu S, Zhang L, Zhao L. LncRNA HOXA-AS2 Activates the Notch Pathway to Promote Cervical Cancer Cell Proliferation and Migration[J]. Reprod Sci. 2021;28(10):3000-3009.

[15] Lu B, Liu Z, Ji X, Zhang X. Assessment of the prognostic and clinicopathological significance of HOXA-AS2 in human cancers: a systematic review and meta-analysis[J]. Transl Cancer Res. 2023; 12(3):605-615.